NasdaqGM:RYTMBiotechs
Rhythm Pharmaceuticals (RYTM) Is Up 7.9% After Promising Early PWS Data for Setmelanotide - What's Changed
In June 2026, Rhythm Pharmaceuticals reported preliminary six-month Phase 2 data for setmelanotide in Prader-Willi syndrome, showing improvements in BMI, body composition, hyperphagia, and anxiety-related behaviors, with safety consistent with prior experience and 17 of 18 patients remaining on therapy.
The breadth of clinically relevant benefits across weight, hunger, and behavioral measures in a difficult-to-treat PWS population could meaningfully influence how investors think about...